logo
Plus   Neg
Share
Email

Takeda Pharma Reports Positive CHMP Opinion For ADCETRIS - Quick Facts

Takeda Pharmaceutical Company Limited (TAK) announced the European Medicines Agency's Committee for Medicinal Products for Human Use has granted a positive opinion for the extension of the marketing authorization of ADCETRIS. The CHMP has recommended the approval of ADCETRIS in combination with cyclophosphamide, doxorubicin, prednisone as a treatment for adult patients with previously untreated systemic anaplastic large cell lymphoma.

Seattle Genetics and Takeda are jointly developing ADCETRIS. Seattle Genetics has U.S. and Canadian commercialization rights and Takeda has rights to commercialize ADCETRIS in the rest of the world.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Moderna said Tuesday that it has reached an agreement with the U.S. to initially supply 100 million doses of its experimental vaccine for COVID-19, mRNA-1273. The U.S. government has awarded up to $1.525 billion for the vaccine. Las Vegas, Nevada-based Mr. Wok Foods has recalled about 200,000 pounds of meat and poultry products for misbranding and undeclared allergens, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS said. The recalled products may contain known allergens such as milk, wheat, soy, peanuts, or oysters. They may also contain MSG, sesame products, or sulfites. The U.S. Food and Drug Administration approved the first oral drug to treat patients two months of age and older with spinal muscular atrophy (SMA) that can be taken at home. Roche subsidiary Genentech's Evrysdi (risdiplam) is also the second FDA-approved drug to treat this rare and often fatal genetic disease affecting muscle strength and movement.
Follow RTT